Biopharmaceutical companies in Pennsylvania play a pivotal role in healthcare innovation. This sector focuses on discovering, developing, and manufacturing medicines derived from biological sources, primarily aiming to address chronic diseases and critical health challenges. Utilizing advanced technologies, companies here engineer vaccines, gene therapies, and protein-based treatments, charting a course towards more personalized medicine. With significant investments and a growing talent pool, Pennsylvania's biopharmaceutical industry is poised for expansive growth, contributing to both local economies and global health solutions.

Pennsylvania is home to a mix of biopharmaceutical companies ranging in size and specialization. Spanning from newer startups to established entities, these companies showcase a broad array of therapeutic focuses including oncology, viral infections, and genetic disorders. Founded primarily within the last two decades, firms like Spark Therapeutics and Tavotek Biotherapeutics illustrate the blend of innovation and expertise flourishing in the state, manifesting in various promising product pipelines.

Continue reading to learn about Pennsylvania's top biopharmaceutical companies.

Top 25 Biopharmaceutical Companies in Pennsylvania

1. Tavotek Biotherapeutics

• Website: tavotek.com
• Ownership type: Corporate
• Headquarters: Lower Gwynedd Township, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 68%, China 32%
• Latest funding: Series B, $35.0M, November 2021
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: tavotek

Tavotek Biotherapeutics, based in Lower Gwynedd Township, Pennsylvania, is a biopharmaceutical company established in 2019. The company is dedicated to discovering, developing, and commercializing therapeutic medicines for patients suffering from serious diseases, including various forms of cancer and autoimmune conditions. Tavotek operates through advanced research and development platforms, such as TavoSelect™, TavoPrecise™, and TavoELITE™, which focus on biologics and target specific medical needs. The company has a robust pipeline of product candidates and is actively involved in clinical trials, including a recent Phase 1 trial for TAVO412, a multispecific biologic targeting solid tumors. Tavotek's management team consists of seasoned professionals with extensive experience in the pharmaceutical industry, enhancing its capability to navigate the complexities of drug development. In November 2021, Tavotek secured $35 million in Series B funding, which bolsters its research initiatives and operational growth.

2. Spark Therapeutics, Inc.

• Website: sparktx.com
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn: spark-therapeutics-inc

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing gene therapy treatments for genetic diseases. Their focus includes conditions like hemophilia and inherited retinal diseases, where traditional therapies may fall short. Spark aims to create innovative, one-time therapies that can provide lasting benefits to patients. The company operates a fully integrated model that combines research, development, and manufacturing of gene therapies. Spark has made significant strides in the industry, highlighted by their flagship product, Luxturna, which is the first approved gene therapy for a genetic disease in both the U.S. and Europe. In 2019, they secured substantial funding of $4.3 billion, underscoring investor confidence in their mission and potential. Spark is also a member of the Roche Group, which enhances their resources and reach in the biopharmaceutical market.

3. SK Life Science Labs

• Website: sklslabs.com
• Ownership type: Private
• Headquarters: King Of Prussia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: proteovant-therapeutics

SK Life Science Labs, based in King of Prussia, Pennsylvania, is a biotechnology firm that concentrates on drug discovery and development. Established in 2021, it operates as a subsidiary of SK Biopharmaceuticals, which is part of the larger SK Group. The company is dedicated to creating innovative therapies for oncology and immunology, utilizing proprietary platforms such as targeted protein degradation and the MOPED™ molecular glue platform. Their work aims to improve treatment outcomes for patients suffering from debilitating diseases. With a team that boasts over 120 years of combined experience in research and development, SK Life Science Labs is positioned to make significant contributions to the biopharmaceutical industry. They collaborate with pharmaceutical companies and research institutions, focusing on advanced treatment solutions. Their pipeline includes multiple discovery programs targeting various cancers and immunological disorders, reflecting their commitment to addressing critical health challenges.

4. Venatorx Pharmaceuticals, Inc.

• Website: venatorx.com
• Ownership type: Venture Capital
• Headquarters: Malvern, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $24.7M, September 2022
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: venatorx-pharmaceuticals-inc.

Venatorx Pharmaceuticals, Inc. is a biopharmaceutical company based in Malvern, Pennsylvania, founded in 2010. The company is dedicated to the discovery and development of innovative anti-infectives aimed at treating multi-drug-resistant bacterial infections and hard-to-treat viral infections. With a robust in-house research and development team, Venatorx has filed over 120 patents and has advanced several of its discovery programs into clinical stages. Their lead product, cefepime-taniborbactam, is currently under FDA review following a successful Phase 3 study for complicated urinary tract infections. In addition to this, Venatorx is developing other promising candidates, including an oral antibacterial and novel PBP inhibitors. The company has also secured significant funding, including a recent contract from BARDA worth up to $318 million, to support the development of its therapies. Venatorx's commitment to addressing the pressing issue of antibiotic resistance positions it as a vital player in the biopharmaceutical industry.

5. KaliVir Immunotherapeutics

• Website: kalivir.com
• Ownership type: Venture Capital
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, March 2022
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: kalivir-immunotherapeutics

KaliVir Immunotherapeutics, based in Pittsburgh, Pennsylvania, is a biotechnology firm that specializes in oncolytic viral immunotherapy aimed at treating cancer. Founded in 2019, the company is dedicated to developing innovative therapies that enhance immune responses against tumors. Their flagship product candidate, VET3-TGI, is designed to target patients with advanced solid tumors, showcasing their commitment to addressing significant unmet medical needs in oncology. KaliVir operates within the biotechnology sector, emphasizing research and development to push the boundaries of cancer treatment. The company is currently involved in clinical trials, including a Phase 1/1b trial that recently commenced, indicating active engagement in the development process. With a team of experienced professionals from various backgrounds in biotechnology and pharmaceuticals, KaliVir is positioned to contribute to advancements in cancer therapy.

6. Evrys Bio

• Website: evrysbio.com
• Ownership type: Private
• Headquarters: Doylestown, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $34.3M, July 2021
• Founded year: 2012
• Headcount: 1-10
• LinkedIn: forge-life-science

Evrys Bio, founded in 2012 and based in Doylestown, Pennsylvania, is a biotechnology firm dedicated to the development of innovative antiviral therapies. The company is pioneering a novel approach by targeting human proteins known as sirtuins, which play a crucial role in the body's immune response to viral infections. This method aims to create broad-spectrum antivirals that can effectively combat multiple viral infections, addressing a significant unmet need in the healthcare sector. Evrys Bio's pipeline includes several promising drug discovery programs, such as treatments for respiratory infections and hepatitis, showcasing their commitment to tackling complex viral challenges. The company has also secured $34.3 million in funding as of July 2021, reflecting strong investor interest in their unique therapeutic strategies.

7. Enterin Inc.

• Website: enterininc.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $5.1M, December 2023
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: enterin-inc.

Enterin Inc. is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2016. The company is dedicated to developing innovative treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's Disease. Enterin's lead drug, ENT-01, is designed to repair the gut-brain axis, a critical pathway that influences neurological health. The company is currently conducting clinical trials, including the KARMET Phase 2b and RASMET Phase 2a studies, to evaluate the efficacy of ENT-01. Recent clinical data suggests that this drug may improve the quality of life for patients by addressing various non-motor symptoms associated with Parkinson's Disease. Enterin has also secured funding, with a reported amount of approximately $5 million in December 2023, which underscores its ongoing efforts to advance its research and development initiatives.

8. Third Arc Bio

• Website: thirdarcbio.com
• Ownership type: Private Equity
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $165.0M, July 2024
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: third-arc-bio

Third Arc Bio, founded in 2022 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing transformational therapies for solid tumors and inflammatory diseases. The company specializes in creating multifunctional antibodies designed to form immune synapses, which are crucial for precisely activating or inhibiting T cells. This innovative approach aims to enhance the effectiveness of immunotherapies. With a team of experienced professionals, including CEO Peter F. Lebowitz, MD, PhD, and CSO Sanjaya Singh, PhD, Third Arc Bio is well-positioned to advance the next generation of biologics. In July 2024, the company successfully raised $165 million in an oversubscribed Series A financing round, underscoring its potential and the interest from investors in its mission to deliver superior treatment solutions for complex diseases.

9. BlueWhale Bio

• Website: bluewhale.bio
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $18.0M, September 2023
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: bluewhale-bio

BlueWhale Bio, Inc. is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2022. The company is dedicated to enhancing cell-based and gene therapies, aiming to improve manufacturing processes to make these therapies more accessible and effective for patients. With a team led by prominent immunotherapy experts Carl June and James Riley from the University of Pennsylvania, BlueWhale Bio is developing a portfolio of innovative products designed to tackle existing bottlenecks in the treatment paradigm. The company has recently raised $18 million in seed funding, indicating strong investor confidence in its mission to transform the landscape of cell therapy. Their target customers include healthcare providers and organizations seeking cutting-edge therapeutic solutions, positioning BlueWhale Bio as a significant player in the biopharmaceutical sector.

10. Peptilogics

• Website: peptilogics.com
• Ownership type: Venture Capital
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), January 2022
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: peptilogics

Peptilogics is a biotechnology firm based in Pittsburgh, Pennsylvania, founded in 2013. The company specializes in developing peptide therapeutics, aiming to revolutionize the drug discovery process for serious and life-threatening diseases. Their primary focus is on innovative solutions for infections, particularly periprosthetic joint infections (PJI), which pose significant health risks and have limited treatment options. Peptilogics is advancing its lead program, PLG0206, which has shown effective in vitro and nonclinical activity and has received FDA orphan drug designation. The company employs a unique AI-driven platform to enhance peptide design and optimize therapeutic properties, allowing for a more efficient and targeted approach to drug development. Peptilogics collaborates with healthcare professionals and engages in clinical trials to bring their therapeutic solutions to market, demonstrating a commitment to addressing high unmet medical needs in the healthcare sector.

11. Noveome Biotherapeutics, Inc.

• Website: noveome.com
• Ownership type: Venture Capital
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series E-K, $51.0M, August 2023
• Founded year: 2000
• Headcount: 11-50
• LinkedIn: noveome-biotherapeutics-inc.

Noveome Biotherapeutics, Inc., based in Pittsburgh, Pennsylvania, is a clinical-stage biopharmaceutical company founded in 2000. The company is dedicated to developing innovative biologics, with a primary focus on ST266, a multi-targeted secretome designed to treat complex diseases in ophthalmology, neurology, and dermatology. Noveome is actively involved in clinical trials and research, aiming to provide effective treatment options for healthcare providers and patients. The company has recently completed a $51 million Series E funding round in August 2023, which underscores its ongoing efforts to advance its therapeutic offerings. Noveome's commitment to scientific progress and patient care is evident in its pipeline and the unique mechanisms of action of its lead product, ST266, which has shown promise in addressing conditions that currently lack adequate treatment options.

12. Integral Molecular

• Website: integralmolecular.com
• Ownership type: Private
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $8.0M, October 2024
• Founded year: 2001
• Headcount: 51-200
• LinkedIn: integral-molecular

Integral Molecular, founded in 2001 and based in Philadelphia, Pennsylvania, is a biotechnology company that specializes in technologies and therapeutic antibodies aimed at membrane protein targets. The company offers a range of services, including antibody discovery, virology reagents, and protein engineering, which are essential for pharmaceutical and biotech firms in developing effective therapies and vaccines. Integral Molecular has worked with more than 100 top-tier companies, demonstrating its significant role in the biopharmaceutical industry. Recently, they secured $8 million in funding through a grant, which highlights their ongoing research and development efforts. Their expertise in membrane proteins, which are critical targets for many drugs, positions them as a key player in advancing therapeutic solutions for complex diseases.

13. Imvax, Inc.

• Website: imvax.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $29.0M, January 2025
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: imvax-inc

Imvax, Inc., founded in 2015 and based in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to developing personalized immunotherapy solutions for solid tumors. The company specializes in creating whole tumor-derived treatments through its proprietary Goldspire™ platform, which aims to harness the full antigen signature of tumors to stimulate the patient's immune response. This innovative approach targets conditions such as glioblastoma, a particularly aggressive form of brain cancer. Imvax is currently involved in multiple clinical trials, including a Phase 2b trial for its lead program, IGV-001, which has shown promising data in newly diagnosed glioblastoma patients. The company is supported by a team of experienced professionals from various sectors of biopharma, and it has recently secured $29 million in funding, reflecting confidence in its potential to deliver impactful therapies.

14. Uniquity Bio

• Website: uniquity.com
• Ownership type: Private Equity
• Headquarters: Malvern, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $300.0M, May 2024
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: uniquity

Uniquity Bio is a clinical-stage drug development company based in Malvern, Pennsylvania, specializing in innovative therapeutics for immune-mediated diseases. Founded in 2022, the company is focused on developing monoclonal antibodies, with its lead asset, solrikitug, targeting thymic stromal lymphopoietin (TSLP). This drug aims to address significant unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Backed by Blackstone Life Sciences, Uniquity Bio has secured $300 million in funding to support its clinical programs. The company is led by a team of seasoned professionals with extensive experience in the biopharmaceutical industry, committed to delivering transformative medicines to patients. Uniquity Bio is actively expanding its pipeline, with a focus on developing high-potential therapeutics that can significantly improve patient outcomes.

15. Fox Chase Therapeutics Discovery, Inc.

• Website: fctdi.com
• Ownership type: Private
• Headquarters: Doylestown, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: fox-chase-chemical-diversity-center-inc.

Fox Chase Therapeutics Discovery, Inc. (FCTDI), based in Doylestown, Pennsylvania, is a private biotechnology company founded in 2008. The firm specializes in drug discovery and development, working closely with pharmacologists and medical professionals to transform research concepts into viable drug candidates. FCTDI leverages a substantial collection of over 34,000 reagents and starting materials, which enhances their ability to conduct lead optimization efficiently. Their commitment to translational research is evident through their collaborations with institutions like The Wistar Institute, where they have contributed significantly to the preparation of thousands of drug candidates. FCTDI has successfully advanced three drug candidates into clinical trials, showcasing their impact on the biopharmaceutical landscape. Their work is supported by various grants, including funding from the National Institutes of Health, which underscores their role in advancing therapeutic solutions for human diseases.

16. Imagine Pharma

• Website: imaginepharma.com
• Ownership type: Venture Capital
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $10.0M, October 2023
• Founded year: 2016
• Headcount: 1-10
• LinkedIn: imagine-pharmaceuticals

Imagine Pharma, based in Pittsburgh, Pennsylvania, is a biotechnology firm established in 2016. The company is dedicated to developing innovative therapies and drug delivery systems, with a particular emphasis on the oral delivery of biologics and regenerative medicine. Their research targets critical health conditions, including diabetes and wound healing, aiming to provide advanced treatment options for patients. Imagine Pharma operates through a robust research and development framework, which is essential for addressing significant unmet medical needs in the healthcare sector. The company has recently secured $10 million in Series A funding, reflecting strong investor interest and support for their mission. With a small team of around 19 employees, Imagine Pharma is positioned to make impactful contributions to the biopharmaceutical industry, focusing on first-in-class treatments that could change patient outcomes.

17. Verismo Therapeutics

• Website: verismotherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $4.0M, January 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: verismo-therapeutics

Verismo Therapeutics, founded in 2020 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing innovative cancer therapies. The company specializes in CAR T cell therapy, particularly targeting solid tumors, which have historically been difficult to treat with existing CAR T approaches. Verismo's KIR-CAR platform is designed to enhance T cell functionality and reduce exhaustion, offering a promising alternative to traditional therapies. The company has made strides in its clinical pipeline, including the activation of clinical trials and receiving FDA clearance for its product candidate SynKIR-310, aimed at treating relapsed or refractory B-cell non-Hodgkin lymphoma. With a small team of experts, many of whom have a history of pioneering work in the field, Verismo is positioned to advance the treatment of challenging cancers and improve patient outcomes. The company has also secured funding, indicating investor confidence in its innovative approach and potential impact in the biopharmaceutical sector.

18. M8 Pharmaceuticals, Inc

• Website: m8pharmaceuticals.com
• Ownership type: Private
• Headquarters: Berwyn, Pennsylvania, United States (USA)
• Employee distribution: Mexico 59%, Brazil 39%, Other 1%
• Latest funding: $125.0M, February 2019
• Founded year: 2007
• Headcount: 201-500
• LinkedIn: moksha8

M8 Pharmaceuticals, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, established in 2007. The company specializes in licensing, marketing, and distributing innovative therapeutics across Latin America, with a significant focus on countries like Mexico and Brazil. M8 collaborates with global pharmaceutical firms to improve access to essential medications, addressing critical health needs in the region. Their portfolio includes therapeutic areas such as central nervous system disorders, cardiometabolism, respiratory issues, gastroenterology, oncology, hematology, and rare diseases. In 2019, M8 Pharmaceuticals secured $125 million in funding, which underscores their growth potential and commitment to expanding their market presence. Recently, the company has signed exclusive agreements for treatments targeting conditions like Type 2 diabetes and osteoarthritis, further solidifying their role in the biopharmaceutical industry. Following their acquisition by Acino, M8 continues to operate under its brand while enhancing its capabilities in Latin America.

19. Interius BioTherapeutics

• Website: interiusbio.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $51.4M, June 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: interius-biotherapeutics

Interius BioTherapeutics is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2019. The company specializes in developing advanced gene therapies, particularly focusing on in vivo cell-specific gene delivery technologies. Their primary aim is to create CAR T cells for treating hematologic malignancies, which are cancers that affect blood cells. Interius operates in the biotechnology and healthcare sectors, catering to patients and healthcare providers seeking cutting-edge treatment options. Recently, the company raised over $51 million in a Series B funding round, indicating strong investor confidence in their innovative approach. They are currently preparing to commence a Phase 1 clinical trial for their lead product, INT2104, which targets B cell malignancies. This investigational therapy aims to generate CAR T and NK cells directly within the patient's body, potentially offering a more efficient and less toxic treatment alternative compared to traditional methods. Interius is also exploring applications beyond oncology, which could expand their impact in the biopharmaceutical industry.

20. Rockland Immunochemicals, Inc.

• Website: rockland-inc.com
• Ownership type: Private
• Headquarters: Limerick Township, Pennsylvania, United States (USA)
• Founded year: 1962
• Headcount: 51-200
• LinkedIn: rockland-immunochemicals-inc-

Rockland Immunochemicals, Inc., founded in 1962 and based in Limerick Township, Pennsylvania, is a biotechnology company that specializes in the production of high-quality antibodies, blood products, and related services. The company caters to researchers in the life sciences sector, providing essential tools for research and diagnostics. Their product offerings include primary and secondary antibodies, blood products, proteins, peptides, and various reagents. Additionally, Rockland offers custom antibody production and analytical services, which are crucial for advancing research in biopharma and diagnostics. Their commitment to quality and customer service has established them as a reliable partner for researchers across multiple industries, including AgBio and emerging therapeutics.

21. Aro Biotherapeutics

• Website: arobiotx.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 96%, Bangladesh 4%
• Latest funding: Series B, $41.5M, November 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: aro-biotherapeutics

Aro Biotherapeutics, based in Philadelphia, Pennsylvania, is a biotechnology firm that specializes in the development of targeted genetic medicines. Established in 2018, the company leverages its proprietary Centyrin platform to create therapeutic candidates aimed at treating complex diseases. Aro's innovative approach combines advances in protein engineering and nucleic acid chemistry to enhance the delivery and efficacy of genetic therapies. Their focus on oligonucleotide-based therapeutics allows them to target gene expression with high specificity, addressing conditions that traditional therapies may not effectively manage. Aro has recently secured $41.5 million in Series B funding, which underscores its potential and the interest it has garnered from investors. The company is actively working on a pipeline of Centyrin-based drug candidates, collaborating with industry partners to bring these advanced solutions to market.

22. NodThera

• Website: nodthera.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 54%, United Kingdom (UK) 38%, France 8%
• Latest funding: Series B, $55.0M, June 2020
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: nodthera-limited

NodThera is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2016. The company specializes in drug discovery and development, with a particular focus on chronic inflammation diseases. Their goal is to create targeted medicines for conditions that currently have limited treatment options. NodThera's team is composed of experienced scientists, industry leaders, and clinicians who are dedicated to advancing the understanding and treatment of chronic inflammation through innovative approaches. The company has successfully raised $55 million in Series B funding as of June 2020, which underscores its potential for growth and development in the biopharmaceutical sector. With a pipeline aimed at addressing significant unmet medical needs, NodThera is actively contributing to the pharmaceutical landscape and is positioned to make a meaningful impact in the treatment of chronic inflammatory diseases.

23. BlueSphere Bio

• Website: bluespherebio.com
• Ownership type: Private
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: bluesphere-bio

BlueSphere Bio, based in Pittsburgh, Pennsylvania, is a biotechnology firm established in 2018. The company is dedicated to developing novel TCR-based therapies aimed at treating various forms of cancer, including hematologic malignancies and solid tumors. Their primary products, TCX-101 and TCX-102, are designed to enhance treatment options for patients who have limited alternatives. TCX-101 is a TCR T-cell therapy that works in conjunction with standard stem cell transplants, while TCX-102 targets patients with specific mutations in acute myeloid leukemia (AML). BlueSphere Bio utilizes its proprietary TCXpress TCR Discovery platform to streamline the development of its therapies, showcasing a commitment to innovation in the biopharmaceutical field. The company’s mission is to provide every cancer patient with a chance for a cure, reflecting a strong focus on improving patient outcomes through advanced therapeutic strategies.

24. Code Biotherapeutics

• Website: codebiotx.com
• Ownership type: Venture Capital
• Headquarters: Hatfield, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $75.0M, June 2022
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: code-biotherapeutics

Code Biotherapeutics, founded in 2020 and based in Hatfield, Pennsylvania, is a biotechnology firm dedicated to advancing genetic medicine. The company specializes in its proprietary 3DNA delivery platform, which is designed to overcome the limitations of traditional gene therapy delivery methods. This innovative platform is particularly focused on treating genetic diseases, with a primary emphasis on Duchenne Muscular Dystrophy (DMD), a severe condition affecting young boys. Code Biotherapeutics is actively developing a pipeline of genetic medicines aimed at various diseases, leveraging its technology to improve targeting and reduce side effects. The company has attracted significant venture capital, securing $75 million in its Series A funding round in June 2022, which underscores its potential in the biopharmaceutical industry. Through partnerships and collaborations, Code Biotherapeutics is working to expand its impact in the field of genetic therapies, making it a noteworthy player in the biopharmaceutical sector.

25. Reaction Biology

• Website: reactionbiology.com
• Ownership type: Private Equity
• Headquarters: Malvern, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 60%, Germany 37%, Other 3%
• Latest funding: March 2022
• Founded year: 2001
• Headcount: 51-200
• LinkedIn: reaction-biology-corporation

Reaction Biology, founded in 2001 and based in Malvern, Pennsylvania, is a biotechnology company that specializes in drug discovery services. With a workforce of approximately 137 employees, the company operates as a private equity entity. Reaction Biology offers a comprehensive suite of assays and testing platforms designed to assist pharmaceutical and biotechnology companies in evaluating drug candidates. Their services include target-specific assays, cell-based assays, biophysical assays, and in vivo pharmacology, among others. The company emphasizes the importance of high-quality data and collaborative support, which are essential for successful drug development. Reaction Biology has a notable presence in the industry, with operations extending to Germany and a client base that includes various pharmaceutical firms. Their commitment to innovation is evident in their extensive portfolio of services, which addresses critical areas such as immuno-oncology and kinase drug discovery.

Biopharmaceutical Insights: Key Companies in Pennsylvania

Want to Find More Biopharmaceutical Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!